STOCK TITAN
  1. Home
  2. News
  3. CDNA

Caredx Inc - CDNA STOCK NEWS

Welcome to our dedicated news page for Caredx (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on Caredx.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Caredx's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Caredx's position in the market.

News
CareDx Hosts Second Annual MEET Digital Health User Conference to Showcase Latest Innovations to Enhance Transplant Patient Care
Rhea-AI Summary
CareDx, Inc. announces its second annual digital health user conference, the Management Expert Exchange in Transplantation (MEET) Conference. The conference aims to bring together transplant administrators, quality managers, clinicians, and organ procurement organization professionals to share best practices and discuss emerging trends in transplant operations. Keynote presentation will be delivered by Dr. David Mulligan, former UNOS President.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.09%
Tags
none
-
News
CareDx Comments on Issuance of Proposed LCD for Molecular Testing for Solid Allograft Rejection
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.06%
Tags
none
-
News
CareDx Reports Second Quarter 2023 Results
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.23%
Tags
earnings
News
CareDx Announces District Court Judge Bars Natera from Falsely Advertising and Overstating the Scientific Performance of its Prospera Transplant Test
Rhea-AI Summary
CareDx, Inc. announced that the United States District Court issued an injunction prohibiting Natera from falsely advertising and overstating the scientific performance of its Prospera transplant test. The court upheld the jury's decision that Natera violated the Lanham Act by engaging in false advertising. Natera made nine false advertising claims regarding its Prospera test.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.7%
Tags
none
-
News
CareDx to Report Second Quarter 2023 Financial Results
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.71%
Tags
conferences earnings
-
News
CareDx’s HeartCare Multimodality Service Receives Medicare Coverage for Heart Transplant Surveillance
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.34%
Tags
none
News
CareDx Acquires MediGO, an Organ Transplant Supply Chain and Logistics Company
Rhea-AI Summary
CareDx, a precision medicine company, has acquired MediGO, a digital health platform, to expand its offerings in the organ procurement organization (OPO) market and improve access to donated organs. The acquisition aims to shorten transplant wait times and increase organ utilization. The combined strengths of the two companies will drive operational efficiencies and accelerate innovation in the transplant ecosystem.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.76%
Tags
acquisition
-
News
CareDx Applauds District Court Decision to Uphold Jury Verdict that Natera Falsely Advertised its Prospera Transplant Test
Rhea-AI Summary
CareDx announces that the United States District Court has upheld the decision that Natera violated the Lanham Act by falsely advertising the scientific performance of its Prospera transplant test.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.88%
Tags
none
-
News
CareDx’s AlloSure Lung dd-cfDNA Testing Service Receives Medicare Coverage for Lung Transplant Rejection Monitoring
Rhea-AI Summary
CareDx's AlloSure Lung, a donor-derived cell-free DNA (dd-cfDNA) molecular testing service, has received Medicare coverage for use in surveillance settings in lung transplant patients. The approval represents a significant milestone for lung transplant patients, as AlloSure Lung is the first dd-cfDNA approved by Medicare for this population. The test has been shown to effectively identify acute cellular rejection, antibody-mediated rejection, and infection in asymptomatic lung transplant patients during routine surveillance screening. It has also been found to reduce the number of invasive biopsies needed for surveillance. AlloSure Lung has already been adopted in over 60 percent of lung transplant centers in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.49%
Tags
none
News
CareDx Demonstrates Innovation Leadership at 2023 Transplant Congress
Rhea-AI Summary
CareDx, Inc. announces a leading presence at the 2023 American Transplant Congress with 65 scientific presentations. The company will showcase the clinical utility of AlloSure Kidney and AlloMap in the surveillance and management of transplant patients. Noteworthy presentations include the use of AlloSure to guide immunosuppression minimization, transition to belatacept therapy, and treatment in patients with T-Cell Mediated Rejection. AlloSure Kidney is also shown to improve early detection of subclinical rejection and predict graft failure. One-year outcomes of patients on rejection surveillance protocol utilizing AlloSure resulted in fewer biopsies and treated rejection episodes. AlloSure Lung can predict CLAD risk equivalent to or better than an invasive biopsy. CareDx will host a symposium on artificial intelligence and molecular diagnostics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
none
Stock CDNA logo
Caredx Inc

Nasdaq:CDNA

CDNA Rankings

#3097 Ranked by Market Cap
#5231 Ranked by Stock Gains
N/A Ranked by Dividends

CDNA Stock Data

441.67M
50.37M
3.75%
100.35%
10%
Medical Laboratories
Health Care and Social Assistance
Link
US
South San Francisco

About CDNA

caredx: transforming transplant patient care through novel surveillance management solutions caredx, inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. by combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, caredx is at the forefront of organ transplant surveillance and pre-transplant hla typing solutions. nasdaq:cdna about allosure® allosure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. allosure is a clinical-grade, proprietary next-generation sequencing (ngs) based test to detect donor-derived cell-free dna (dd-cfdna) in order to identify organ injury in kidney transplant recipients. allosure is analytically validated as a sensitive, specific, and precise measurement of dd-cfdna. allos